Quotient Clinical and Upperton announce a spray drying partnership to deliver integrated formulation development and GMP manufacturing programs for poorly soluble drugs

Quotient Clinical, the Translational Pharmaceutics® company, and Upperton, the UK spray drying specialist, have announced a partnership to address drug delivery challenges.  This venture will combine Upperton’s formulation development services with Quotient’s GMP manufacturing services.

Over 40% of candidate drugs in development are poorly soluble which leads to low oral bioavailability. Spray drying is a widely adopted and successful approach to addressing this issue.

Mark Egerton, CEO of Quotient Clinical said

“Spray drying is a key technology and is an established capability within our service portfolio. Upperton has more than 20 years’ spray drying expertise and this partnership will both reinforce our existing spray drying know-how and extend our capabilities into biologics, offering new and exciting opportunities”.

Richard Johnson, CEO and Founder of Upperton added

“We are really pleased to announce this partnership with Quotient. It allows us to streamline the transfer of formulation development projects into pilot GMP manufacturing, better supporting our customers’ preclinical and clinical development needs. Our first joint program has already been successfully delivered and has demonstrated the time savings that can be achieved for our customers through our close working relationship with Quotient”.